AMERIGUARD SECURITY SERVICES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AMERIGUARD SECURITY SERVICES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.44M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $20.97M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $24.95M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $22.44M | Sep 15, 2023 |
| FY2013 | Dec 31, 2013 | $7.31M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $5.81M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $1.43M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $1.14M | Jul 31, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $7.10M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $5.81M | Apr 15, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.00M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $1.81M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $3.00M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $1.81M | Sep 15, 2023 |
| FY2013 | Dec 31, 2013 | $3.25M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $2.98M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $959.1K | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $842.3K | Jul 31, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.34M) | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $103.6K | May 12, 2025 |
| FY2023 | Dec 31, 2022 | ($436.8K) | May 8, 2025 |
| FY2021 | Dec 31, 2021 | ($3.9K) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($21.4K) | Mar 31, 2022 |
| FY2013 | Dec 31, 2013 | ($5.47M) | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | ($1.46M) | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | ($1.17M) | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $142.3K | Jul 31, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.40M) | May 12, 2025 |
| FY2024 | Dec 31, 2023 | ($2.43M) | May 12, 2025 |
| FY2023 | Dec 31, 2022 | ($82.3K) | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $128.0K | Sep 15, 2023 |
| FY2020 | Dec 31, 2020 | ($745.6K) | Jun 14, 2021 |
| FY2013 | Dec 31, 2013 | ($4.80M) | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | ($992.1K) | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | ($1.14M) | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $157.1K | Jul 31, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $64.4K | Apr 1, 2013 |
| FY2011 | Dec 31, 2011 | $93.5K | Apr 16, 2012 |
| FY2011 | Dec 31, 2010 | $73.7K | Apr 16, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.1K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $8.1K | Mar 31, 2022 |
| FY2013 | Dec 31, 2013 | $7.02M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $3.85M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $1.98M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $594.9K | Jul 31, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.61M) | May 12, 2025 |
| FY2024 | Dec 31, 2023 | ($87.7K) | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $258.1K | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $276.7K | Sep 15, 2023 |
| FY2021 | Dec 31, 2020 | ($21.4K) | Mar 31, 2022 |
| FY2013 | Dec 31, 2013 | ($3.37M) | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | ($1.70M) | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | ($65.6K) | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $187.2K | Jul 31, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $10.3K | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $21.0K | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $47.0K | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $325.0K | Jul 31, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.82M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $7.84M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $3.75M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $4.59M | Sep 15, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Jun 14, 2021 |
| FY2013 | Dec 31, 2013 | $5.43M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $2.78M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $736.6K | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $596.0K | Jul 31, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.94M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $8.62M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.75M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $2.60M | Sep 15, 2023 |
| FY2020 | Dec 31, 2020 | $25.6K | Jun 14, 2021 |
| FY2013 | Dec 31, 2013 | $7.66M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $2.59M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $1.10M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $465.0K | Jul 31, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.12M) | May 12, 2025 |
| FY2024 | Dec 31, 2023 | ($783.8K) | May 12, 2025 |
| FY2024 | Dec 31, 2022 | ($2.00M) | May 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.48M | May 8, 2025 |
| FY2021 | Sep 30, 2021 | ($6.7K) | Mar 31, 2022 |
| FY2021 | Jun 30, 2021 | ($33.7K) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($30.8K) | Mar 31, 2022 |
| FY2022 | Dec 31, 2020 | $2.86M | Sep 15, 2023 |
| FY2021 | Sep 30, 2020 | ($21.4K) | Mar 31, 2022 |
| FY2013 | Dec 31, 2013 | ($4.15M) | Apr 15, 2014 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.80M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $1.80M | May 12, 2025 |
| FY2024 | Oct 31, 2023 | $1.80M | May 12, 2025 |
| FY2023 | Sep 30, 2023 | $1.80M | May 8, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.28M) | May 12, 2025 |
| FY2024 | Dec 31, 2023 | ($943.7K) | May 12, 2025 |
| FY2023 | Dec 31, 2022 | ($2.16M) | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $1.82M | Sep 15, 2023 |
| FY2021 | Dec 31, 2020 | ($10.04M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $424.6K | May 12, 2025 |
| FY2024 | Dec 31, 2023 | $2.17M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.23M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | $2.13M | Sep 15, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Jun 14, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $316.4K | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $219.0K | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $502.1K | Apr 1, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | May 12, 2025 |
| FY2024 | Dec 31, 2023 | 0 | May 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 4, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | May 12, 2025 |
| FY2024 | Dec 31, 2023 | 0 | May 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 8, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 94.92M | May 12, 2025 |
| FY2024 | Dec 31, 2023 | 94.92M | May 12, 2025 |
| FY2023 | Dec 31, 2022 | 94.92M | May 8, 2025 |
| FY2022 | Dec 31, 2021 | 94.47M | Sep 15, 2023 |
| FY2021 | Dec 31, 2020 | 68.35M | Mar 31, 2022 |
| FY2013 | Dec 31, 2013 | 54.75M | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | 39.05M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | 16.50M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | 1.02M | Jul 31, 2012 |